Schedule 13G/A Amendment: Janus Henderson Reports 0% in LRMR
Rhea-AI Filing Summary
Janus Henderson Group plc filed Amendment No. 5 to a Schedule 13G reporting its position in Larimar Therapeutics, Inc. (CUSIP 517125100). The filing states that Janus Henderson and certain indirect subsidiaries beneficially own 0 shares of Larimar common stock, representing 0.0% of the class. The report lists Janus Henderson as Type IA, HC with a principal address at 201 Bishopsgate, EC2M 3AE, United Kingdom, and shows 0 sole and shared voting and dispositive powers. The filing names JHIUS, JHIUKL and JHIAIFML as indirect subsidiaries providing investment advice to Managed Portfolios and includes a power of attorney dated December 9, 2022. The statement is signed by Kristin Mariani on 08/14/2025.
Positive
- Filed Amendment No. 5 with clear disclosure of ownership showing 0 shares (0.0%) beneficially owned
- Includes an executed power of attorney (Dec 9, 2022), supporting the filer’s ability to make timely regulatory submissions
Negative
- None.
Insights
TL;DR Janus Henderson reports no beneficial stake in LRMR; this is a routine ownership disclosure with no market-moving implications.
The Schedule 13G/A shows 0 shares (0.0%) beneficially owned and zero voting or dispositive power. From an investor-impact perspective, the filing conveys that Janus Henderson holds no position that could influence Larimar's control or voting outcomes. The amendment and included power-of-attorney exhibit indicate the firm is maintaining regulatory compliance for ownership reporting.
TL;DR Filing appears procedurally complete: identifies reporting entity, confirms no holdings, and attaches a power of attorney for filings.
The document names Janus Henderson Group plc (Type: IA, HC), provides issuer and filer addresses, and specifies subsidiaries (JHIUS, JHIUKL, JHIAIFML) that advise Managed Portfolios. The explicit statement of 0 sole/shared voting and dispositive powers and the executed power of attorney (Dec 9, 2022) support timely compliance. This is a regulatory disclosure rather than a substantive change in ownership.
FAQ
What stake does Janus Henderson report in Larimar Therapeutics (LRMR)?
What form and amendment was filed for LRMR?
Who is the reporting person on the filing for LRMR?
Do any subsidiaries of Janus Henderson appear in the filing?
When was the filing signed and who signed it?
AI-generated analysis. How Rhea-AI works. Not financial advice.